Cargando…

Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by pathogenic variants in genes encoding for LDL receptor (LDLR), Apolipoprotein B and Proprotein convertase subtilisin/kexin type 9 (PCSK9). Among PCSK9 variants, only Gain-of- Function (GOF) variants lead to FH. Greater att...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Taranto, Maria Donata, Benito-Vicente, Asier, Giacobbe, Carola, Uribe, Kepa Belloso, Rubba, Paolo, Etxebarria, Aitor, Guardamagna, Ornella, Gentile, Marco, Martín, Cesar, Fortunato, Giuliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681505/ https://www.ncbi.nlm.nih.gov/pubmed/29127338 http://dx.doi.org/10.1038/s41598-017-15543-x

Ejemplares similares

Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement
por: Di Taranto, Maria Donata, et al.
Publicado: (2021)

A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia
por: Di Taranto, Maria Donata, et al.
Publicado: (2020)

Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis
por: Di Taranto, Maria Donata, et al.
Publicado: (2023)

Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
por: Benito-Vicente, Asier, et al.
Publicado: (2018)

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
por: Uribe, Kepa B., et al.
Publicado: (2021)

Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies
por: Larrea-Sebal, Asier, et al.
Publicado: (2023)

Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants
por: Benito-Vicente, Asier, et al.
Publicado: (2018)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Calpain-Mediated Processing of Adenylate Cyclase Toxin Generates a Cytosolic Soluble Catalytically Active N-Terminal Domain
por: Uribe, Kepa B., et al.
Publicado: (2013)

Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject
por: Larrea-Sebal, Asier, et al.
Publicado: (2023)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Adenylate Cyclase Toxin promotes bacterial internalisation into non phagocytic cells
por: Martín, César, et al.
Publicado: (2015)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Galectin-3 in Cardiovascular Diseases
por: Blanda, Valeria, et al.
Publicado: (2020)

Ca(2+) Influx and Tyrosine Kinases Trigger Bordetella Adenylate Cyclase Toxin (ACT) Endocytosis. Cell Physiology and Expression of the CD11b/CD18 Integrin Major Determinants of the Entry Route
por: Uribe, Kepa B., et al.
Publicado: (2013)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
por: Louloudis, Georgios, et al.
Publicado: (2021)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
por: Banerjee, Poulabi, et al.
Publicado: (2019)

Corrigendum: Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
por: Louloudis, Georgios, et al.
Publicado: (2022)

Advantages and Versatility of Fluorescence-Based Methodology to Characterize the Functionality of LDLR and Class Mutation Assignment
por: Etxebarria, Aitor, et al.
Publicado: (2014)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
por: Seidah, Nabil G.
Publicado: (2021)

Cardiovascular Disease, Atherosclerosis and Familial Hypercholesterolemia: From Molecular Mechanisms Causing Pathogenicity to New Therapeutic Approaches
por: Jebari-Benslaiman, Shifa, et al.
Publicado: (2023)

PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
por: Kaya, Esra, et al.
Publicado: (2017)

The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women
por: Evans, David, et al.
Publicado: (2006)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

Calprotectin Levels and Neutrophil Count Are Prognostic Markers of Mortality in COVID-19 Patients
por: Cardiero, Giovanna, et al.
Publicado: (2022)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018)

Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
por: Galicia-Garcia, Unai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pa2d734in4noha0r5edlfrvrbo